Under the deal, Tilray and Sandoz will supply nonsmokable and noncombustible medical cannabis products where they are legal. In addition, the two companies may co-brand certain products and develop new ones.
“This agreement represents a major milestone in the movement to provide access to safe, GMP-certified medical cannabis to patients in need across the world,” said Tilray CEO Brendan Kennedy.
The agreement marks the first of its kind for medical marijuana and a major milestone for the pharma industry, STAT reports.
More articles on pharmacy:
Pharmaceutical company files for bankruptcy, receives $200M takeover bid
Merck’s global human health president to step down, advise CEO
Kroger launches discount program for out-of-pocket prescription drugs
